Following another loss in federal court, Indivior does not seem like it will be able to stop Dr. Reddy’s Laboratories’ launch of a generic version of its drug Suboxone, a blockbuster treatment for opioid dependence that makes up most of the company’s sales. Mylan and Alvogen also have generics on the way. Suboxone currently holds preferred formulary status for 51% of all covered lives. Indivior said Suboxone could lose 80% of its market share in just a few months after a generic launch, which could happen as early as next week.
SOURCE: MMIT Analytics, as of 2/6/19